IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation

IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor

(2021) Yuying Liu et al.   NATURE IMMUNOLOGY

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

(2021) Ghulam Rehman Mohyuddin et al.   Blood Advances

FDA approves first BCMA-targeted CAR-T cell therapy

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma

(2020) Lorena Perez-Amill et al.   HAEMATOLOGICA

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

(2020) Vanessa Pinto et al.   Cancers

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

(2020) Leila Jafarzadeh et al.   Frontiers in Immunology

Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma

(2020) Ester Lozano et al.   CLINICAL CANCER RESEARCH

Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword

(2020) Anthony M. Battram et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

(2020) Paweł Robak et al.   MEDIATORS OF INFLAMMATION

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions

(2020) Luis Gerardo Rodríguez-Lobato et al.   Frontiers in Oncology

DCAF1 regulates Treg senescence via the ROS axis during immunological aging

(2020) Zengli Guo et al.   JOURNAL OF CLINICAL INVESTIGATION

CAR T cell therapies for patients with multiple myeloma

(2020) Lekha Mikkilineni et al.   Nature Reviews Clinical Oncology

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020

(2020) Arthur Bobin et al.   Cancers

IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity

(2019) Darya Alizadeh et al.   Cancer Immunology Research

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

(2019) Mattia D’Agostino et al.   LEUKEMIA

B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis

(2019) Nico Gagelmann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Signaling and Function of Interleukin-2 in T Lymphocytes

(2018) Sarah H. Ross et al.   Annual Review of Immunology

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2—A Balancing Act

(2018) Vandana Kalia et al.   Frontiers in Immunology

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay

(2016) Jinsheng Weng et al.   OncoImmunology

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates

(2015) Giulia Di Lullo et al.   OncoImmunology

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

(2015) Yun Bai et al.   Cell Discovery

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

(2012) Xiuli Wang et al.   JOURNAL OF IMMUNOTHERAPY

Reversible Senescence in Human CD4+CD45RA+CD27- Memory T Cells

(2011) D. Di Mitri et al.   JOURNAL OF IMMUNOLOGY

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

IL-15 Regulates Both Quantitative and Qualitative Features of the Memory CD8 T Cell Pool

(2009) Michelle M. Sandau et al.   JOURNAL OF IMMUNOLOGY